Cell-type, Dose, and Mutation-type Specificity Dictate Mutant p53 Functions In Vivo

Cancer Cell

Volumn 22, Issue 6, 2012, Pages 751-764

  Lee, Ming Kei ^a   Teoh, Wei Wei ^a   Phang, Beng Hooi ^a   Tong, Wei Min ^b   Wang, Zhao Qi ^c,d   Sabapathy, Kanaga ^a,e,f  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c FRITZ LIPMANN INSTITUTE   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; HISTIDINE; PACLITAXEL; PROTEIN MDM2; PROTEIN P53; SERINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL DEATH; CELL SPECIFICITY; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; DOMINANT NEGATIVE MUTATION; EX VIVO STUDY; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; IN VIVO STUDY; LYMPHOMA; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIATION DOSE; THYMOMA; TRANSACTIVATION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84870828710     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.10.022     Document Type: Article

References (38)

1. Bossi G., Lapi E., Strano S., Rinaldo C., Blandino G., Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006, 25:304-309.
2. Brosh R., Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 2009, 9:701-713.
3. Chan W.M., Siu W.Y., Lau A., Poon R.Y. How many mutant p53 molecules are needed to inactivate a tetramer?. Mol. Cell. Biol. 2004, 24:3536-3551.
4. Christophorou M.A., Ringshausen I., Finch A.J., Swigart L.B., Evan G.I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006, 443:214-217.
5. Gaiddon C., Lokshin M., Ahn J., Zhang T., Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 2001, 21:1874-1887.
6. Jackson E.L., Olive K.P., Tuveson D.A., Bronson R., Crowley D., Brown M., Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005, 65:10280-10288.
7. Jones S.N., Roe A.E., Donehower L.A., Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995, 378:206-208.
8. Junttila M.R., Evan G.I. p53-a Jack of all trades but master of none. Nat. Rev. Cancer 2009, 9:821-829.
9. Kemp C.J., Wheldon T., Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat. Genet. 1994, 8:66-69.
10. Kern S.E., Pietenpol J.A., Thiagalingam S., Seymour A., Kinzler K.W., Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992, 256:827-830.
11. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119:861-872.
12. Lee M.K., Sabapathy K. The R246S hot-spot p53 mutant exerts dominant-negative effects in embryonic stem cells in vitro and in vivo. J. Cell Sci. 2008, 121:1899-1906.
13. Lee M.K., Tong W.M., Wang Z.Q., Sabapathy K. Serine 312 phosphorylation is dispensable for wild-type p53 functions in vivo. Cell Death Differ. 2011, 18:214-221.
14. Levine A.J., Momand J., Finlay C.A. The p53 tumour suppressor gene. Nature 1991, 351:453-456.
15. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74:957-967.
16. Milner J., Medcalf E.A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 1991, 65:765-774.
17. Monti P., Perfumo C., Bisio A., Ciribilli Y., Menichini P., Russo D., Umbach D.M., Resnick M.A., Inga A., Fronza G. Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes. Mol. Cancer Res. 2011, 9:271-279.
18. Morton J.P., Timpson P., Karim S.A., Ridgway R.A., Athineos D., Doyle B., Jamieson N.B., Oien K.A., Lowy A.M., Brunton V.G., et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc. Natl. Acad. Sci. USA 2010, 107:246-251.
19. Muller P.A., Caswell P.T., Doyle B., Iwanicki M.P., Tan E.H., Karim S., Lukashchuk N., Gillespie D.A., Ludwig R.L., Gosselin P., et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009, 139:1327-1341.
20. O'Shea D., O'Riain C., Taylor C., Waters R., Carlotti E., Macdougall F., Gribben J., Rosenwald A., Ott G., Rimsza L.M., et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 2008, 112:3126-3129.
21. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847-860.
22. Olivier M., Hollstein M., Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2010, 2:a001008.
23. Oren M., Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2010, 2:a001107.
24. Palmero E.I., Achatz M.I., Ashton-Prolla P., Olivier M., Hainaut P. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr. Opin. Oncol. 2010, 22:64-69.
25. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007, 28:622-629.
26. Robles A.I., Harris C.C. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb. Perspect. Biol. 2010, 2:a001016.
27. Schmitt C.A., McCurrach M.E., de Stanchina E., Wallace-Brodeur R.R., Lowe S.W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999, 13:2670-2677.
28. Terzian T., Suh Y.A., Iwakuma T., Post S.M., Neumann M., Lang G.A., Van Pelt C.S., Lozano G. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 2008, 22:1337-1344.
29. Toh W.H., Nam S.Y., Sabapathy K. An essential role for p73 in regulating mitotic cell death. Cell Death Differ. 2010, 17:787-800.
30. Varley J.M., Evans D.G., Birch J.M. Li-Fraumeni syndrome-a molecular and clinical review. Br. J. Cancer 1997, 76:1-14.
31. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
32. Vikhanskaya F., Lee M.K., Mazzoletti M., Broggini M., Sabapathy K. Cancer-derived p53 mutants suppress p53-target gene expression-potential mechanism for gain of function of mutant p53. Nucleic Acids Res. 2007, 35:2093-2104.
33. Wang Y., Suh Y.A., Fuller M.Y., Jackson J.G., Xiong S., Terzian T., Quintás-Cardama A., Bankson J.A., El-Naggar A.K., Lozano G. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J. Clin. Invest. 2011, 121:893-904.
34. Weisz L., Oren M., Rotter V. Transcription regulation by mutant p53. Oncogene 2007, 26:2202-2211.
35. Wijnhoven S.W., Zwart E., Speksnijder E.N., Beems R.B., Olive K.P., Tuveson D.A., Jonkers J., Schaap M.M., van den Berg J., Jacks T., et al. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res. 2005, 65:8166-8173.
36. Wijnhoven S.W., Speksnijder E.N., Liu X., Zwart E., vanOostrom C.T., Beems R.B., Hoogervorst E.M., Schaap M.M., Attardi L.D., Jacks T., et al. Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. Cancer Res. 2007, 67:4648-4656.
37. Yeudall W.A., Vaughan C.A., Miyazaki H., Ramamoorthy M., Choi M.Y., Chapman C.G., Wang H., Black E., Bulysheva A.A., Deb S.P., et al. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 2012, 33:442-451.
38. Zilfou J.T., Lowe S.W. Tumor suppressive functions of p53. Cold Spring Harb. Perspect. Biol. 2009, 1:a001883.